Aburatani Tomoki, Inokuchi Mikito, Takagi Yoko, Ishikawa Toshiaki, Okuno Keisuke, Gokita Kentaro, Tomii Chiharu, Tanioka Toshiro, Murase Hideaki, Otsuki Sho, Uetake Hiroyuki, Kojima Kazuyuki, Kawano Tatsuyuki
Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Department of Surgical Specialty, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Oncol Lett. 2017 Jul;14(1):404-410. doi: 10.3892/ol.2017.6115. Epub 2017 May 3.
P21-activated kinase 5 (PAK5), also termed PAK7, is one of the six members of the PAK family of serine/threonine kinases, which are downstream effectors in several cancer signaling pathways. PAK5 promotes neural outgrowth, contributes to microtubule stability and induces resistance to apoptosis. However, the clinical importance of PAK5 in gastric cancer has not been comprehensively investigated. In the present study, PAK5 expression was evaluated in gastric cancer tissue samples. Furthermore, the associations between high expression of PAK5, and clinicopathological features and prognosis were examined. PAK5 expression in primary gastric cancer specimens resected from 279 patients who underwent gastrectomy at the Tokyo Medical and Dental University Hospital was evaluated using immunohistochemistry. Of the 279 patients, 44 (15.8%) exhibited high PAK5 expression, which was significantly associated with the differentiated pathological type (differentiated vs. undifferentiated; P<0.001), depth of tumor invasion (T1 vs. T2-T4; P<0.001), lymph node metastasis (N0 vs. N1-N3; P<0.001), presence of distant metastasis or recurrence (present vs. absent; P=0.038), advanced tumor stage (I vs. II-IV; P=0.001) and worse disease-specific survival (P=0.013). In stage I-III disease, 38/254 (15.0%) patients exhibited high PAK5 expression, and high expression of PAK5 was significantly associated with relapse-free interval (P=0.044). PAK5 may serve an important role in tumor progression and influence the outcome of patients with gastric cancer.
p21激活激酶5（PAK5），也称为PAK7，是丝氨酸/苏氨酸激酶PAK家族六个成员之一，是多种癌症信号通路的下游效应器。PAK5促进神经生长，有助于微管稳定性并诱导抗凋亡。然而，PAK5在胃癌中的临床重要性尚未得到全面研究。在本研究中，评估了胃癌组织样本中PAK5的表达。此外，还研究了PAK5高表达与临床病理特征及预后之间的关联。采用免疫组织化学方法评估了东京医科齿科大学医院279例行胃切除术患者的原发性胃癌标本中PAK5的表达。在这279例患者中，44例（15.8%）表现出PAK5高表达，这与病理分化类型（分化型与未分化型；P<0.001）、肿瘤浸润深度（T1与T2-T4；P<0.001）、淋巴结转移（N0与N1-N3；P<0.001）、远处转移或复发的存在（存在与不存在；P=0.038）、肿瘤晚期（I期与II-IV期；P=0.001）以及较差的疾病特异性生存率（P=0.013）显著相关。在I-III期疾病中，254例患者中有38例（15.0%）表现出PAK5高表达，PAK5高表达与无复发生存期显著相关（P=0.044）。PAK5可能在肿瘤进展中起重要作用，并影响胃癌患者的预后。
